Evidence map›Paper›PMID 35950266›Full record

ReviewWiley interdisciplinary reviews. Nanomedicine and nanobiotechnology2023

Immunomodulation in age-related disorders and nanotechnology interventions.

Uday Chintapula, Tanmayee Chikate, Deepsundar Sahoo, Amie Kieu, Ingrid D Guerrero Rodriguez, Kytai T Nguyen, Daniel Trott

Open access · greenAbstract readReview
In one paragraph

Review in Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Carbon Dots Derived fromInternational journal of nanomedicine · 2024
    Article
  8. Modified Rice Bran Arabinoxylan byMolecules (Basel, Switzerland) · 2023
    Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Uday ChintapulaDepartment of Bioengineering, University of Texas at Arlington, Arlington, Texas, USA.ORCID 0000-0002-6028-4485
Tanmayee ChikateDepartment of Bioengineering, University of Texas at Arlington, Arlington, Texas, USA.
Deepsundar SahooDepartment of Bioengineering, University of Texas at Arlington, Arlington, Texas, USA.ORCID 0000-0002-9372-8599
Amie KieuDepartment of Bioengineering, University of Texas at Arlington, Arlington, Texas, USA.
Ingrid D Guerrero RodriguezDepartment of Bioengineering, University of Texas at Arlington, Arlington, Texas, USA.ORCID 0000-0003-2190-3439
Kytai T NguyenDepartment of Bioengineering, University of Texas at Arlington, Arlington, Texas, USA.
Daniel TrottDepartment of Kinesiology, University of Texas at Arlington, Arlington, Texas, USA.
The University of Texas at Arlington · US

Funding

IMPACT OF T CELLS ON AGE-RELATED VASCULAR DYSFUNCTION: A TRANSLATIONAL APPROACH - DIVERSITY SUPPLEMENTR01AG060395 · NIA · UNIVERSITY OF UTAH · PI DONATO, ANTHONY JOHN · 2019 to 2023
$2.5M
Novel nanoparticles to stimulate therapeutic angiogenesis in peripheral arterial diseaseR01HL158204 · NHLBI · UNIVERSITY OF TEXAS ARLINGTON · PI LIU, LI, NGUYEN, KYTAI TRUONG · 2022 to 2025
$2.2M
Interdisciplinary Training in Nanotechnology for Cardiovascular and Lung Diseases in North TexasT32HL134613 · NHLBI · UNIVERSITY OF TEXAS ARLINGTON · PI NGUYEN, KYTAI TRUONG · 2017 to 2021
$1.1M
T cells mediate age related arterial dysfunctionK01AG061271 · NIA · UNIVERSITY OF TEXAS ARLINGTON · PI TROTT, DANIEL · 2019 to 2023
$635k
Synergistic Upregulation of EpoR /RopE NPs for Enhancing Effective Angiogenesis to treat PADR15HL156076 · NHLBI · UNIVERSITY OF TEXAS ARLINGTON · PI NGUYEN, KYTAI TRUONG · 2021 to 2021
$443k
NHLBI NIH HHS R01 HL158204NHLBI NIH HHS R15 HL156076NHLBI NIH HHS T32 HL134613NIA NIH HHS K01 AG061271NIA NIH HHS R01 AG060395
6 · The paper itself

Abstract

Recently, the aging population has increased exponentially around the globe bringing more challenges to improve quality of life in those populations while reducing the economic burden on healthcare systems. Aging is associated with changes in the immune system culminating in detrimental effects such as immune dysfunction, immunosenescence, and chronic inflammation. Age-related decline of immune functions is associated with various pathologies including cardiovascular, autoimmune, neurodegenerative, and infectious diseases to name a few. Conventional treatment addresses the onset of age-related diseases by early detection of risk factors, administration of vaccines as preventive care, immunomodulatory treatment, and other dietary supplements. However, these approaches often come with systemic side-effects, low bioavailability of therapeutic agents, and poor outcomes seen in the elderly. Recent innovations in nanotechnology have led to the development of novel biomaterials/nanomaterials, which explore targeted drug delivery and immunomodulatory interactions in vivo. Current nanotechnology-based immunomodulatory approaches that have the potential to be used as therapeutic interventions for some prominent age-related diseases are discussed here. Finally, we explore challenges and future aspects of nanotechnology in the treatments of age-related disorders to improve quality of life in the elderly. This article is categorized under: Therapeutic Approaches and Drug Discovery > Nanomedicine for Cardiovascular Disease Therapeutic Approaches and Drug Discovery > Nanomedicine for Neurological Disease Therapeutic Approaches and Drug Discovery > Emerging Technologies.

Indexed as

Cardiovascular DiseasesImmunomodulationNanomedicineNanoparticlesNervous System DiseasesAgedDrug Delivery SystemsHumansQuality of Lifeage-related diseasesagingimmunomodulationnanoparticlesnanotechnology

Identifiers

PMID35950266
PMCPMC9840662
OpenAlexW4292712492

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.